Morphine/dextromethorphan - Endo

Drug Profile

Morphine/dextromethorphan - Endo

Alternative Names: Dextromethorphan/morphine - Endo; EN 3231; MorphiDex

Latest Information Update: 11 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endo Pharmaceuticals
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer pain

Most Recent Events

  • 11 Jul 2006 Discontinued - Phase-III for Cancer pain in USA (PO)
  • 10 Jan 2003 Phase-III clinical trials in Cancer pain in USA (PO)
  • 30 Oct 2002 MorphiDex did not meet primary and secondary endpoints in the two phase III studies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top